Advances in BABE

In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

  • Application of Nano technology to improve bioavailabilty
  • Innovative strategies
  • Isotope drug studies in man
  • Bioequivalence Criteria
  • Risks in bioequivalence assessment
  • Requirement to determine the active principle
  • SUPAC: scale-up and for post-approval changes
  • Relevance of bioequivalence in approving generic copies of drug products
  • Electronic regulatory submission and review
  • Drug application regulatory compliance
  • New drug quality assessment
  • Highly variable and low permeable drugs
  • Complex generics

Related Conference of Advances in BABE

February 28-March 01, 2019 ANA Crowne Plaza |

Global Pharmaceutical and Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
July 26-27, 2019

13th Asian Biologics and Biosimilars Congress

Mercure Albert Park | Melbourne, Australia

Advances in BABE Conference Speakers

Recommended Sessions

Related Journals

Are you interested in